DESCRIPTION

This practical guide presents a road map for safety assessment as an integral part of the development of new drugs and therapeutics.

- Helps readers solve scientific, technical, and regulatory issues in preclinical safety assessment and early clinical drug development

- Explains scientific and philosophical bases for evaluation of specific concerns – including local tissue tolerance, target organ toxicity and carcinogenicity, developmental toxicity, immunogenicity, and immunotoxicity

- Covers the development of new small and large molecules, generics, 505(b)(2) route NDAs, and biosimilars

- Revises material to reflect new drug products (small synthetic, large proteins and cells, and tissues), harmonized global and national regulations, and new technologies for safety evaluation

- Adds almost 20% new and thoroughly updates existing content from the last edition

ABOUT THE AUTHOR

Shayne Cox Gad, BS, PhD, DABT, has more than 39 years of experience in regulatory toxicology, drug and device development, statistics, and risk assessment. He is Principal of Gad Consulting Services, a firm with eight employees and more than 500 clients worldwide in the pharmaceutical and medical device industries. He is Past President of the American College of Toxicology (ACT), the Roundtable of Toxicology Consultants, and three of the Society of Toxicology’s specialty sections. Dr. Gad received the 2008
ACT Lifetime Contribution Award and has authored or edited 47 books (10 with Wley) and more than 350 chapters, articles, and abstracts. Has prepared 110 INDs and 8 NDAs and teaches 3-5 professional education courses a year.

SERIES

Pharmaceutical Development Series

For additional product details, please visit https://www.wiley.com/en-us